GSK-2983559

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H23N4O7PS2
Molecular Weight	538.534
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)S(=O)(=O)C1=C(OCCOP(O)(O)=O)C=C2N=CN=C(NC3=CC4=C(SC=N4)C=C3)C2=C1

InChI

InChIKey=MJLYDVMFNHZMLV-UHFFFAOYSA-N

InChI=1S/C21H23N4O7PS2/c1-21(2,3)35(29,30)19-9-14-15(10-17(19)31-6-7-32-33(26,27)28)22-11-23-20(14)25-13-4-5-18-16(8-13)24-12-34-18/h4-5,8-12H,6-7H2,1-3H3,(H,22,23,25)(H2,26,27,28)

HIDE SMILES / InChI

Molecular Formula	C21H23N4O7PS2
Molecular Weight	538.534
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase RIPK2 4 Target ID: CHEMBL5014 Sources: https://patents.google.com/patent/WO2014043446A1	Inhibitor 8504

C_max

Value	Dose	Co-administered	Analyte	Population
314.2321 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
351.0316 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
2717.46 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2950.11 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
104.28 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
257.28 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
405.39 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
911.53 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2860.23 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
10.48 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.526 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.044 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.304 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.649 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.717 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.799 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03358407?tab=results	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2983559 ACTIVE METABOLITE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Patents

Substance Class	Chemical Created by `admin` on `Wed Apr 02 20:35:53 GMT 2025` Edited by `admin` on `Wed Apr 02 20:35:53 GMT 2025`
Record UNII	WJY2LV4368
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GSK-2983559 free acid

Preferred Name

English

GSK-2983559

Code

English

2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate

Systematic Name

English

Ethanol, 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-, 1-(dihydrogen phosphate)

Systematic Name

English

Code System Code Type Description

PUBCHEM

73386708

Created by admin on Wed Apr 02 20:35:53 GMT 2025 , Edited by admin on Wed Apr 02 20:35:53 GMT 2025

PRIMARY

CAS

1579965-12-0

Created by admin on Wed Apr 02 20:35:53 GMT 2025 , Edited by admin on Wed Apr 02 20:35:53 GMT 2025

PRIMARY

SMS_ID

300000042507

Created by admin on Wed Apr 02 20:35:53 GMT 2025 , Edited by admin on Wed Apr 02 20:35:53 GMT 2025

PRIMARY

FDA UNII

WJY2LV4368

Created by admin on Wed Apr 02 20:35:53 GMT 2025 , Edited by admin on Wed Apr 02 20:35:53 GMT 2025

PRIMARY

Related Record Type Details


					ICA29PPR3N

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2

TARGET -> INHIBITOR

Amount:


					2DFS6M9JDJ

GSK-2983559 hydrochloride

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					2893X36L7K

GSK-2983559 active metabolite

METABOLITE ACTIVE -> PRODRUG

Amount:

Related Record Type Details


					2893X36L7K

GSK-2983559 active metabolite

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

Approval Year

Targets

Cmax

AUC

T1/2

Patents

C_max

T_1/2